Cyca Onco Solutions, bagged the best startup award at ‘She Loves Tech’ awards. The competition was held at Women Startup Summit 2019 at Kerala Start-up Mission(KSUM), Kochi. She Loves Tech global startup competition, is a large, worldwide platform for women entrepreneurs, as well as startups dedicated to improve the lives of women. More than 20 startups elevated their pitches at the competition.
Teja Ventures founding partner Virginia Tan, addressed the audience over live video. She spoke of the “She Loves Tech” that she initiated in 2015, and the steady progress the movement had made across continents over the four years, to become the world’s largest female technology startup competition.
Virginia Tan, founder, She Loves Tech, said: “She Loves Tech is a global platform committed to building an ecosystem for technology, entrepreneurship and innovation that creates opportunities for women. We are looking forward for more women entrepreneurs to empower them. This competition is the world’s largest tech startup competition focused on women-led or women-impact businesses.”
Filmmaker, Mrs Anjali Menon, spoke during the valedictory function of the ‘Women Startup Summit’, held at the Integrated Startup Complex. Ms Nusrat Sanghamitra of Cyca Onco Solutions, who emerged winner in the national grand challenge of She Loves Tech 2019 Global Start up Competition, held on the sidelines of ‘Women Startup Summit’, received the award from Anjali Menon.
Anjali Menon, said: “Women need not highlight the aspect of their gender. Instead, they must virtually forget it, so as to succeed in their chosen professions. We don’t live in the friendliest of ecosystems, but then, to stay afloat, along an unfavorable current, is, in itself, a great achievement.”
Cyca Onco Solutions has developed two molecular nanomachines — CyPlatin and CyGIobiofor, a programmed drug-delivery service. They work as a high-speed, high-precision drug-delivery device, which can be characterized as a molecular drilling machine. These carry drugs across the cell membrane, and delivers drugs precisely at its cellular target site with 1/10th dose. This improves the quality of life of 15 million cancer patients worldwide, advance the global fight against cancer, and reduce the public health burden.